NCT03417544CompletedPhase 2
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast Cancer
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain. The names of the study drugs involved in this study are: * Atezolizumab * Pertuzumab * Trastuzumab
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- First submitted
- 16 Jan 2018
- Start date
- 21 May 2018
- Primary completion date
- 20 May 2020
- Lead sponsor
- Nancy Lin, MD
- Diseases
- Metastatic breast cancer
- NCT number
- NCT03417544
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 19
- From 21 May 2018 to the primary completion date, 20 May 2020
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
This page is information, not medical advice. Discuss any trial with your doctor.